Descriptions

C-C motif chemokine 21 (CCL21) is chemokine that inhibits hemopoiesis and stimulates chemotaxis, and may play a role in mediating homing of lymphocytes to secondary lymphoid organ. CCL21 has an unstructured C-terminus that does not adopt a stable fold. This C-terminal tail of CCL21 makes autoinhibitory contacts with and modulates the structure and function of the CCL21 chemokine domain. CCL21's C-terminus transiently interacts with the chemokine domain of CCL21, thereby providing a putative structural correlate of functional autoinhibition.

Autoinhibitory domains (AIDs)

Target domain

1-79 (Chemokine domain)

Relief mechanism

PTM

Assay

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q8HYP5

Entry ID Method Resolution Chain Position Source
AF-Q8HYP5-F1 Predicted AlphaFoldDB

No variants for Q8HYP5

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for Q8HYP5

6 associated diseases with Q8HYP5

[MIM: 603689]: Myopathy, myofibrillar, 9, with early respiratory failure (MFM9)

An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support. {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 613765]: Cardiomyopathy, familial hypertrophic 9 (CMH9)

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 604145]: Cardiomyopathy, dilated 1G (CMD1G)

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11788824, ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 600334]: Tardive tibial muscular dystrophy (TMD)

Autosomal dominant, late-onset distal myopathy. Muscle weakness and atrophy are usually confined to the anterior compartment of the lower leg, in particular the tibialis anterior muscle. Clinical symptoms usually occur at age 35-45 years or much later. {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 608807]: Muscular dystrophy, limb-girdle, autosomal recessive 10 (LGMDR10)

An autosomal recessive degenerative myopathy characterized by progressive weakness of the pelvic and shoulder girdle muscles. Severe disability is observed within 20 years of onset. {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 611705]: Salih myopathy (SALMY)

An autosomal recessive, early-onset muscular disorder characterized by dilated cardiomyopathy, delayed motor development with generalized muscle weakness predominantly affecting proximal and distal lower limbs. Skeletal muscle biopsies show minicore-like lesions with mitochondrial depletion and sarcomere disorganization, centralized nuclei, and type 1 fiber predominance. Dystrophic changes become apparent in the second decade. Cardiac muscle biopsies show disruption of myocardial architecture, nuclear hypertrophy, and endomysial fibrosis. Sudden death may occurr due to cardiomyopathy. {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID
  • An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support. {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants affecting the gene represented in this entry.
  • A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by variants affecting the gene represented in this entry.
  • A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11788824, ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The disease is caused by variants affecting the gene represented in this entry.
  • Autosomal dominant, late-onset distal myopathy. Muscle weakness and atrophy are usually confined to the anterior compartment of the lower leg, in particular the tibialis anterior muscle. Clinical symptoms usually occur at age 35-45 years or much later. {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The disease is caused by variants affecting the gene represented in this entry.
  • An autosomal recessive degenerative myopathy characterized by progressive weakness of the pelvic and shoulder girdle muscles. Severe disability is observed within 20 years of onset. {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants affecting the gene represented in this entry.
  • An autosomal recessive, early-onset muscular disorder characterized by dilated cardiomyopathy, delayed motor development with generalized muscle weakness predominantly affecting proximal and distal lower limbs. Skeletal muscle biopsies show minicore-like lesions with mitochondrial depletion and sarcomere disorganization, centralized nuclei, and type 1 fiber predominance. Dystrophic changes become apparent in the second decade. Cardiac muscle biopsies show disruption of myocardial architecture, nuclear hypertrophy, and endomysial fibrosis. Sudden death may occurr due to cardiomyopathy. {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants affecting the gene represented in this entry.

9 regional properties for Q8HYP5

Type Name Position InterPro Accession
domain SANT/Myb domain 160 - 263 IPR001005-1
domain SANT/Myb domain 442 - 490 IPR001005-2
domain SET domain 626 - 747 IPR001214
domain CXC domain 517 - 619 IPR026489
domain Tesmin/TSO1-like CXC domain 569 - 607 IPR033467
domain Polycomb repressive complex 2 subunit EZH1/EZH2, tri-helical domain 159 - 262 IPR041343
domain Pre-SET CXC domain 573 - 604 IPR041355
domain EZH2, SET domain 623 - 742 IPR044439
domain EZH1/2, MCSS domain 270 - 322 IPR048358

Functions

Description
EC Number
Subcellular Localization
  • Secreted
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
extracellular space That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.

3 GO annotations of molecular function

Name Definition
CCR chemokine receptor binding Binding to a CCR chemokine receptor.
chemokine activity The function of a family of small chemotactic cytokines; their name is derived from their ability to induce directed chemotaxis in nearby responsive cells. All chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of cells during normal processes of tissue maintenance or development. Chemokines are found in all vertebrates, some viruses and some bacteria.
chemokine receptor binding Binding to a chemokine receptor.

10 GO annotations of biological process

Name Definition
cellular response to interleukin-1 Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus.
cellular response to tumor necrosis factor Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus.
cellular response to type II interferon Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon gamma is the only member of the type II interferon found so far.
chemokine-mediated signaling pathway The series of molecular signals initiated by a chemokine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.
G protein-coupled receptor signaling pathway The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane.
inflammatory response The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
lymphocyte chemotaxis The directed movement of a lymphocyte in response to an external stimulus.
monocyte chemotaxis The movement of a monocyte in response to an external stimulus.
neutrophil chemotaxis The directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding.
positive regulation of ERK1 and ERK2 cascade Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.

4 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
O00585 CCL21 C-C motif chemokine 21 Homo sapiens (human) EV
P84444 Ccl21a C-C motif chemokine 21a Mus musculus (Mouse) SS
P86792 Ccl21b C-C motif chemokine 21b Mus musculus (Mouse) SS
P86793 Ccl21c C-C motif chemokine 21c Mus musculus (Mouse) SS
10 20 30 40 50 60
MAQSLALSLL ILVLAFGIPG TQGSDGGAQD CCLKYSQRKI PAKVVRSYRK QEPSLGCSIP
70 80 90 100 110 120
AILFLPRKRS QAELCADPKE LWVQQLMQHL DKTPTPRKPV QGCRKDRGVP KNGKKGKGCK
130
RTEQSQTPKG P